As of September 30, 2026, TELA Bio, Inc. carries a market capitalization of 51.91M, placing it among publicly traded companies globally. Its enterprise value stands at 86.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 51.91M |
| Enterprise Value | 86.08M |
TELA Bio, Inc.'s next confirmed earnings release is scheduled for March 25, 2027.
| Earnings Date | 3/25/2027 |
As of September 30, 2026, TELA Bio, Inc. has 45.14M shares outstanding.
| Shares Outstanding | 45.14M |
These figures are as of September 30, 2026. The price-to-sales ratio is 0.82, and the price-to-book ratio stands at -2.11.
| PS Ratio | 0.82 |
| PB Ratio | -2.11 |
| P/TBV Ratio | -2.02 |
| P/FCF Ratio | -1.87 |
| P/OCF Ratio | -1.89 |
These figures are as of September 30, 2026. The EV/Sales ratio of 1.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 86.08M versus a market cap of 51.91M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1.10 |
As of September 30, 2026, TELA Bio, Inc. maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -231.25, indicating conservative leverage, while an interest coverage ratio of -4.16 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.61 |
| Quick Ratio | 0.44 |
| Debt / Equity | -231.25 |
| Debt / EBITDA | -1.74 |
| Interest Coverage | -4.16 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -75.40, reflecting losses generated across the asset base. The company generates approximately 358,614.68 in revenue per employee across its workforce of 218.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.21 indicates how many times TELA Bio, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -75.40 |
| Revenue Per Employee | 358,614.68 |
| Employee Count | 218.00 |
| Inventory Turnover | 2.21 |
Over the twelve months ended September 30, 2026, TELA Bio, Inc. recorded 368,000.00 in income tax expense. The company reported a pretax loss of -41.51M and -41.88M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 368,000.00 |
As of the close on November 16, 2026, TELA Bio, Inc.'s stock has declined approximately 23.79% over the past 52 weeks. The 50-day moving average sits at 1.03, while the 200-day moving average is 0.85.
| 52-Week Price Change | -23.79% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 0.85 |
Over the twelve months ended September 30, 2026, TELA Bio, Inc. generated 78.18M in revenue and converted that into -41.88M in net income, yielding earnings per share of -0.75. EBITDA reached -32.72M, while operating income came in at -33.75M.
| Revenue | 78.18M |
| Gross Profit | 52.53M |
| Operating Income | -33.75M |
| Pretax Income | -41.51M |
| Net Income | -41.88M |
| EBITDA | -32.72M |
| EBIT | -33.75M |
| Earnings Per Share (EPS) | -0.75 |
As of September 30, 2026, TELA Bio, Inc. holds 22.66M in cash and equivalents against 56.83M in total debt, resulting in a net debt position of 33.64M. Total book value stands at -24.58M, with working capital of -28.26M providing operational flexibility.
| Cash & Cash Equivalents | 22.66M |
| Total Debt | 56.83M |
| Net Debt | 33.64M |
| Equity (Book Value) | -24.58M |
| Book Value Per Share | -0.54 |
| Working Capital | -28.26M |
TELA Bio, Inc. produced -34.11M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -276,000.00 in capital expenditures, free cash flow totaled -34.39M - equivalent to -0.61 per share.
| Operating Cash Flow | -34.11M |
| Capital Expenditures | -276,000.00 |
| Free Cash Flow | -34.39M |
| FCF Per Share | -0.61 |
Over the twelve months ended September 30, 2026, TELA Bio, Inc. posted a gross margin of 67.19, reflecting its pricing power and cost economics. The operating margin of -43.17 and net profit margin of -53.57 provide insight into operational efficiency.
| Gross Margin | 67.19 |
| Operating Margin | -43.17 |
| Pretax Margin | -53.10 |
| Profit Margin | -53.57 |
| EBITDA Margin | -41.86 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -53.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -49.08, meaning TELA Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -49.08 |
| FCF Yield | -53.39 |
As of September 30, 2026, TELA Bio, Inc. has an Altman Z-Score of -13.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.41 |